Redmile Group’s Aprea Therapeutics APRE Stock Holding History

Redmile Group’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-34,746	Closed	-$3.55M	–	73
2021 Q3	$3.55M	Hold	34,746	–	–	0.06%	70
2021 Q2	$3.39M	Hold	34,746	–	–	0.05%	82
2021 Q1	$3.54M	Sell	34,746 -28,690	-45%	-$3.35M	0.05%	81
2020 Q4	$6.24M	Sell	63,436 -50,000	-44%	-$23.8M	0.08%	76
2020 Q3	$54.6M	Hold	113,436	–	–	1%	34
2020 Q2	$88M	Hold	113,436	–	–	1.62%	18
2020 Q1	$78.9M	Hold	113,436	–	–	2.21%	12
2019 Q4	$104M	Buy	+113,436	New	+$62.5M	2.49%	14

Other funds holding APRE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PDT Partners New York $1.9B AUM 71.86% 1-Year Est. Return

Redmile Group's APRE Position: Q4 2021 in Review

Redmile Group sold out of Aprea Therapeutics (APRE) in Q4 2021, closing a stake of 34,746 shares — an estimated $3.55M sold.

Redmile Group first reported a position in APRE in Q4 2019 and held it in 8 quarters. The position peaked at $104M in Q4 2019. 41 funds tracked by Wall St. Rank hold APRE as of Q4 2021.

Redmile Group reported no remaining Aprea Therapeutics position as of Q4 2021 after selling out during the quarter.
Redmile Group sold 34,746 Aprea Therapeutics shares in Q4 2021, an estimated $3.55M.
Redmile Group first reported a position in Aprea Therapeutics in Q4 2019 and held it in 8 quarters.
Redmile Group's Aprea Therapeutics position peaked at $104M in Q4 2019.
41 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q4 2021.

Based on Redmile Group's 13F filing for Q4 2021, filed 14 Feb 2022.